A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 8/3/2016 |
| Start Date: | June 2005 |
| End Date: | July 2006 |
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to
placebo in patients with type 2 diabetes. The anticipated time on study treatment is < 3
months and the target sample size is 100-500 individuals.
placebo in patients with type 2 diabetes. The anticipated time on study treatment is < 3
months and the target sample size is 100-500 individuals.
Inclusion Criteria:
- adult patients 18-75 years of age;
- type 2 diabetes diagnosed >=1 month before screening;
- no previous treatment, or previous treatment with no more than 2 oral medications.
Exclusion Criteria:
- type 1 diabetes;
- type 2 diabetes treated with insulin or a PPAR gamma agonist during the 3 months
before screening;
- patients who are pregnant, breastfeeding or not using a reliable contraceptive
method.
We found this trial at
19
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials